REAP uses genetically barcoded yeast to present the human exoproteome. Genetic barcoding allows reactivities to be tested in a massively multiplex manner.

By testing thousands of reactivities in a single well, Seranova’s REAP platform achieves unprecedented scale and insight into patient autoreactivities.

Up to 90% of antibodies recognize conformational epitopes as opposed to linear peptides. Therefore, it’s critical to detect reactivities to conformational epitopes.

Seranova’s REAP platform uses yeast to display full-length, correctly folded proteins, ensuring reactivities to conformational epitopes are detected.

Autoantibodies that target extracellular and secreted proteins (collectively, the “exoproteome”) exert potent biological effects that shape health and disease. Prior to REAP, these reactivities were difficult to detect accurately at scale.

By focusing on the exoproteome, Seranova detects the most impactful autoantibody reactivites.

Seranova’s REAP technology has revolutionized the detection of autoantibody reactivities with sensitive, scalable results.

Seravista’s machine learning models are refined with data from every new patient, continuously improving our understanding of the role of different autoantibodies in disease.

Seravista brings together our high-quality autoantibody data with rich  clinical information to generate the disease insights that enable first-in-class therapeutics